Invivyd Advances Measles Antibody Candidate VMS063 and Updates COVID-19 Trial Progress
IVVD has more than doubled off its 52-week low of $0.46.
Summary
Invivyd announced significant progress in its COVID-19 antibody program, including a study upsizing and FDA alignment for pediatric trials, alongside the advancement of a novel measles monoclonal antibody candidate, VMS063.
Key Events · Product Development and Regulatory · IVVD
-
Measles Antibody Advancement
Invivyd announced the discovery and advancement of VMS063, a novel, highly potent, half-life-extended monoclonal antibody candidate for the treatment and prevention of measles, targeting IND readiness in late 2026.
-
COVID-19 Trial Upsizing
The Phase 3 DECLARATION study for VYD2311 was upsized by approximately 500 subjects to increase statistical power, shifting top-line results from 'mid-year' to Q3 2026.
-
Pediatric Study Alignment
Invivyd aligned with the FDA on an Initial Pediatric Study Plan for the BLA-directed 'DRUMMER' clinical trial for VYD2311 in children aged 0-11 years, contingent on DECLARATION study success.
Analysis · IVVD · Life Sciences
This filing highlights Invivyd's strategic expansion into new infectious disease areas while progressing its existing COVID-19 program. The introduction of VMS063, a potentially first-in-class measles antibody, addresses a critical unmet medical need amid rising measles cases and could be a significant future value driver for the company. While the DECLARATION study for VYD2311 sees a modest delay in top-line results, the increased sample size enhances statistical power, and the FDA alignment on a pediatric study plan provides a clear path for broader application. For a company with a recent 'going concern' warning, these pipeline advancements are crucial for demonstrating long-term viability and growth potential.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IVVD was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $381.5M. The 52-week trading range was $0.46 to $3.07. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.